# Roivant Sciences (ROIV) — News

ROIV · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/roiv/news

## Recent headlines

- [Roivant continues to own 19.5% Arbutus stake after tender offer](https://www.ainvest.com/news/roivant-continues-19-5-arbutus-stake-tender-offer-2610) — AInvest Wire, Oct 6, 2026
- [Arbutus: Roivant Sciences to maintain ~19.5% stake after offer](https://www.ainvest.com/news/arbutus-roivant-sciences-maintain-19-5-stake-offer-2609) — AInvest Wire, Sep 30, 2026
- [Roivant Sciences shares down 1.4% premarket; co announces topline results from proof-of-concept study of imvt-1402 in cutaneous lupus erythematosus](https://www.ainvest.com/news/roivant-sciences-shares-1-4-premarket-announces-topline-results-proof-concept-study-imvt-1402-cutaneous-lupus-erythematosus-2609) — AInvest Wire, Sep 23, 2026
  Roivant Sciences Ltd. shares were down 1.4% in premarket trading on September 23, 2026, following the company’s announcement of topline results from a proof-of-concept study of its investigational drug Imvt-1402 in patients with cutaneous lupus erythematosus [1]. The study aimed to evaluate the…
- [Roivant announces topline results from proof-of-concept study](https://www.ainvest.com/news/roivant-announces-topline-results-proof-concept-study-2609) — AInvest Wire, Sep 23, 2026
  Roivant Sciences has announced topline results from a proof-of-concept study evaluating its experimental drug for a type of pulmonary hypertension. The drug, mosliciguat, achieved its primary endpoint, demonstrating a statistically significant 56% reduction in pulmonary vascular resistance compared…
- [Roivant Sciences Ltd: Stifel initiates coverage with buy rating; target price $51](https://www.ainvest.com/news/roivant-sciences-stifel-initiates-coverage-buy-rating-target-price-51-2609) — AInvest Wire, Sep 17, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).